Clinical Trials Logo

Gastric Cancer Third Line clinical trials

View clinical trials related to Gastric Cancer Third Line.

Filter by:
  • None
  • Page 1

NCT ID: NCT02625623 Completed - Clinical trials for Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Start date: December 28, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.